In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 4, 2011, Pages 370-377

  Rudramurthy, Shivaprakash M ^a   Chakrabarti, Arunaloke ^a   Geertsen, Erik ^b   Mouton, Johan W ^b,c   Meis, Jacques F ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal susceptibility; Aspergillus flavus; EUCAST; Wild type cut off value

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; NITRILES; PYRIDINES; TRIAZOLES;

EID: 82555166966     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.08.006     Document Type: Article

References (50)

1. Alcazar-Fuoli L., Rodriguez-Tudela J.L., Mellado E. Antifungal drug resistance in moulds: clinical and microbiological factors. Curr. Fungal Infect Rep. 2008, 2:36-42.
2. Baddley J.W., Marr K.A., Andes D.R., Walsh T.J., Kauffman C.A., Kontoyiannis D.P., Ito J.I., Balajee S.A., Pappas P.G., Moser S.A. Susceptibility patterns of Aspergillus isolates recovered from patients enrolled in the transplant associated infection surveillance network (TRANSNET). J. Clin. Microbiol. 2009, 47:3271-3275.
3. Balajee S.A., Kano R., Baddley JW Moser S.A., Marr K.A., Alexander B.D., Andes D., Kontoyiannis D.P., Perrone G., Peterson S., Brandt M.E., Pappas P.G., Chiller T. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 2009, 47:3138-3141.
4. Calvo E., Pastor F.J., Mayayo E., Salas V., Guarro J. In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrob. Agents Chemother. 2011, 55:1290-1292.
5. Carrillo-Munoz A.J., Ruesga M., Brio S., del Valle O., Rodriguez V., Santos P., Hernandez-Molina J.M., Canton E., Peman J., Guarro J., Quindos G. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P. Chemotherapy 2002, 48:224-231.
6. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Monzon A., Buitrago M.J., Rodriguez- Tudela J.L. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob. Agents Chemother. 2009, 53:2192-2195.
7. De Hoog G.S., Guarro J., Gene J., Figueras J. Atlas of clinical fungi CD ROM 2009, Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands. 3rd ed.
8. De La Escalera C., Martin Aller A.I., Lopez-Oviedo E., Romero A., Martos A.I., Canton E., Peman J., Garcia Martos P., Martin-Mazuelos E. Activity of BAL 4815 against filamentous fungi. J. Antimicrob. Chemother. 2008, 61:1083-1086.
9. De Valk H.A., Meis J.F., de Pauw B.E., Donnelly P.J., Klaassen C.H. Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis. J. Clin. Microbiol. 2007, 45:1415-1419.
10. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 1998, 26:781-803.
11. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., Ullmann A.J., Seibel N.L., Flynn P.M., van Bruik J.A., Buell D.N., Patterson T.F. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 2006, 53:337-349.
12. Diekema D.J., Messer A., Hollis R.J., Jones R.N., Pfaller M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 2003, 41:3623-3626.
13. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 2001, 39:954-958.
14. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion E-test procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 2003, 41:403-409.
15. Espinel-Ingroff A., Fothergill A., Peter J., Rinaldi M.G., Walsh T.J. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 2002, 40:3204-3208.
16. Ford S., Friedman L. Experimental study of the pathogenicity of aspergilli for mice. J. Bacteriol. 1967, 94:928-933.
17. Guinea J., Pelaez T., Recio S., Torres- Narbona M., Bouza E. In vitro antifungal activities of isavuconazole (BAL 4815), voriconazole, and fluconazole against 1,007 isolate of Zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 2008, 52:1396-1400.
18. Hedayati M.T., Pasqualotto A.C., Warn P.A., Bowyer P., Denning D.W. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007, 153:1677-1692.
19. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., Kern W.V., Marr K.A., Ribaud P., Lotholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., de Pauw B. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347:408-415.
20. Herbrecht R., Maertens J., Baila L., Aoun M., Heinz W., Martino R., Schwartz S., Ullmann A.j., Meert L., Paesmans M., Marchetti O., Akan H., Ameye L., Shivaprakash M., Viscoli C. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organization for Research and Treatment of Cancer study. Bone Marrow Transplant. 2010, 45:1227-1233.
21. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fischer M.C., Pasqualotto A.C., Leverdiere M., Arendrup M.C., Perlin D.S., Denning D.W. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 2009, 15:1068-1076.
22. Klaassen C.H., de Valk H.A., Curfs-Breuker I.M., Meis J.F. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J. Antimicrob. Chemother. 2010, 65:901-905.
23. Lass-Florl C., Cuenca-Estrella M., Denning D.W., Rodriguez-Tudela J.L. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med. Mycol. 2006, 44(Suppl. 3):19-25.
24. Lass-Florl C., Mayr A., Perkhofer S., Hinterberger G., Hausdorfer J., Speth C., Fille M. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 2008, 52:3637-3641.
25. Lass-Florl C., Speth C., Kofler G., Dierch M.P., Gunsilius E., Wurzner R. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int. J. Antimicrob. Agents 2003, 21:229-233.
26. Lionakis M.S., Lewis R.L., Torres H.A., Albert N.D., Raad I.I., Kontoyiannis D.P. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn. Microbiol. Infect. Dis. 2005, 52:15-20.
27. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., Sable C.A., Kartsonis N.A., Ngai A., Patterson T.F., Denning D.W., Walsh T.J. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 2004, 39:1563-1571.
28. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., Fridkin S.K., Pappas P.G., Warnock D.W. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med. Mycol. 2005, 43(Suppl. 1):49-58.
29. Oakley K.L., Moore C.B., Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 1998, 42:2726-2730.
30. Odds F.C., Gerven F.V., Espinel-Ingroff A., Bartlett M.S., Ghannoum M.A., Lancaster M.V., Pfaller M.A., Rinaldi M.G., Walsh T.J. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 1998, 42:282-288.
31. Pasqualotto A.C. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med. Mycol. 2009, 47(Suppl. 1):261-270.
32. Perkhofer S., Lechner V., Lass-Florl C. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 2009, 53:1645-1647.
33. Pfaller M.A., Boyken L.B., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 2009, 47:3323-3325.
34. Pfaller M.A., Boyken L.B., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 2010, 67:56-60.
35. Pfaller M.A., Boyken L.B., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. Comparison of the broth microdilution methods of the European Committee on antimicrobial susceptibility testing and the clinical and laboratory standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus species. J. Clin. Microbiol. 2011, 49:1110-1112.
36. Pfaller M.A., Messer S.A., Boyken L.B., Rice C., Tendolkar S., Hollis R.J., Diekema D.J. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 2008, 46:2568-2572.
37. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob. Agents Chemother. 2002, 46:1032-1037.
38. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izuierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2008, 52:2468-2472.
39. Rodriguez-Tudela J.L., Gomez-Lopez A., Arendrup M.C., Garcia-Effron G., Perlin D.S., Lass-Florl C., Cuenca-Estrella M. Comparison of caspofungin MICs by means of EUCAST method EDef 7.1 using two different concentrations of glucose. Antimicrob. Agents Chemother. 2010, 54:3056-3057.
40. Ruiz-Cendoya M., Rodriguez M., Marine M., Pastor J., Guarro J. In vitro interaction of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents 2008, 32:418-420.
41. Rudramurthy S.M., de Valk H.A., Chakrabarti A., Meis J.F., Klaassen C.H. High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites. PloS One 2011, 6:e16086.
42. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., Loebenberg D., Black T.A., McNicholas P.M. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 2006, 50:2009-2015.
43. Seo K., Akiyoshi H., Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol. Immunol. 1999, 43:1017-1025.
44. Shivaprakash M.R., Geertsen E., Chakrabarti A., Mouton J.W., Meis J.F. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011, 54. [Epub ahead of print]. 10.1111/j.1439-0507.2010.01996.x.
45. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. Clin. Microbiol. Infect. 2008, 14:982-984.
46. Verweij P.E., Howard S.J., Melchers W.J.G., Denning D.W. Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug. Res. Updates 2009, 12:141-147.
47. Verweij P.E., Mellado E., Melchers W.J. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 2007, 356:1481-1483.
48. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., van Burik J. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008, 46:327-360.
49. Warn P.A., Sharp A., Denning D.W. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 2006, 57:135-138.
50. Yamazaki T., Inagaki Y., Fujii T., Ohwada J., Tsukazaki M., Umeda I., Kobayashi K., Shimma N., Page M.G., Arisawa M. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents 2010, 36:324-331.